Cerus Stock Price, News & Analysis (NASDAQ:CERS) $1.65 +0.03 (+1.85%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$1.59▼$1.6850-Day Range$1.25▼$1.7952-Week Range$1.21▼$4.25Volume997,929 shsAverage Volume1.33 million shsMarket Capitalization$298.98 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Cerus MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside104.5% Upside$3.38 Price TargetShort InterestHealthy3.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.22) to ($0.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.71 out of 5 starsMedical Sector769th out of 960 stocksSurgical & Medical Instruments Industry66th out of 75 stocks 3.2 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.38, Cerus has a forecasted upside of 104.5% from its current price of $1.65.Amount of Analyst CoverageCerus has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.34% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Cerus has recently decreased by 3.04%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 6 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.05% of the stock of Cerus is held by insiders.Percentage Held by Institutions81.72% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.22) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 4.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cerus Stock (NASDAQ:CERS)Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.Read More CERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERS Stock News HeadlinesNovember 6, 2023 | finance.yahoo.comPositive week for Cerus Corporation (NASDAQ:CERS) institutional investors who lost 54% over the past yearNovember 3, 2023 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) Q3 2023 Earnings Call TranscriptDecember 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 2, 2023 | finance.yahoo.comCerus Corporation Announces Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comCerus (CERS) Reports Q3 Loss, Lags Revenue EstimatesNovember 2, 2023 | finance.yahoo.comCerus Corp (CERS) Q3 2023 Earnings: Product Revenue Stable, Operating Expenses Decrease by 4%November 1, 2023 | businesswire.comBloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital MarketplaceOctober 19, 2023 | finance.yahoo.comCerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023December 7, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 10, 2023 | finance.yahoo.comCerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual MeetingSeptember 27, 2023 | finance.yahoo.comCerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources OfficerSeptember 12, 2023 | finance.yahoo.comCerus Corporation to Participate in the 2023 Cantor Global Healthcare ConferenceAugust 11, 2023 | seekingalpha.comCerus: Profitability Needs To Come Faster As Cash Is Running OutAugust 2, 2023 | sfgate.comCerus: Q2 Earnings SnapshotAugust 2, 2023 | finance.yahoo.comCerus Corporation Announces Second Quarter 2023 Financial ResultsAugust 2, 2023 | finance.yahoo.comCerus (CERS) Reports Q2 Loss, Lags Revenue EstimatesJuly 31, 2023 | finance.yahoo.comCerus (NASDAQ:CERS) investors are sitting on a loss of 60% if they invested three years agoJuly 21, 2023 | nasdaq.comCerus Corporation Common Stock (CERS)July 19, 2023 | finance.yahoo.comCerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023June 15, 2023 | finance.yahoo.comCerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT CongressJune 14, 2023 | finance.yahoo.comCerus Corporation Celebrates World Blood Donor Day 2023June 5, 2023 | seekingalpha.comCerus bags additional $8.7M contract amendmentJune 5, 2023 | finance.yahoo.comCerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized CryoprecipitateMay 30, 2023 | finance.yahoo.comWith 72% institutional ownership, Cerus Corporation (NASDAQ:CERS) is a favorite amongst the big gunsMay 18, 2023 | msn.comCerus Earnings Perspective: Return On Capital EmployedMay 4, 2023 | finance.yahoo.comCerus Corporation Announces First Quarter 2023 Financial ResultsMay 4, 2023 | finance.yahoo.comCerus (CERS) Reports Q1 Loss, Lags Revenue EstimatesSee More Headlines Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees665Year Founded1991Price Target and Rating Average Stock Price Target$3.38 High Stock Price Target$3.75 Low Stock Price Target$3.00 Potential Upside/Downside+105.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,780,000.00 Net Margins-32.40% Pretax Margin-32.13% Return on Equity-84.23% Return on Assets-23.16% Debt Debt-to-Equity Ratio1.22 Current Ratio1.88 Quick Ratio1.35 Sales & Book Value Annual Sales$153.63 million Price / Sales1.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book4.21Miscellaneous Outstanding Shares181,197,000Free Float168,423,000Market Cap$297.16 million OptionableOptionable Beta1.20 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. William M. Greenman (Age 56)President, CEO & Director Comp: $1.33MMr. Kevin D. Green (Age 51)VP of Finance & CFO Comp: $748.49kMr. Vivek K. Jayaraman (Age 48)Chief Operating Officer Comp: $861.67kMs. Chrystal Jensen (Age 52)Chief Legal Officer & General Counsel Comp: $692.16kDr. Richard J. Benjamin (Age 63)Chief Medical Officer Comp: $719.74kDr. Laurence M. Corash (Age 79)Co-Founder & Chief Scientific Officer Comp: $697.77kMs. Lori L. RollVP of Administration & Corporate SecretaryMr. Matthew M. NotarianniSenior Director of Investor RelationsLainie CortenVice President of Global MarketingMs. Alicia GoodmanChief Human Resources OfficerMore ExecutivesKey CompetitorsUtah Medical ProductsNASDAQ:UTMDOraSure TechnologiesNASDAQ:OSURAtrionNASDAQ:ATRITactile Systems TechnologyNASDAQ:TCMDAVITA MedicalNASDAQ:RCELView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 15,448 shares on 11/24/2023Ownership: 0.043%Graham Capital Management L.P.Bought 41,805 shares on 11/22/2023Ownership: 0.030%Polar Capital Holdings PlcSold 1,229,786 shares on 11/22/2023Ownership: 0.026%Walleye Capital LLCBought 1,807,318 shares on 11/21/2023Ownership: 0.997%Walleye Trading LLCBought 75,838 shares on 11/21/2023Ownership: 0.042%View All Insider TransactionsView All Institutional Transactions CERS Stock Analysis - Frequently Asked Questions Should I buy or sell Cerus stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CERS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERS, but not buy additional shares or sell existing shares. View CERS analyst ratings or view top-rated stocks. What is Cerus' stock price target for 2024? 3 brokers have issued 12 month price objectives for Cerus' shares. Their CERS share price targets range from $3.00 to $3.75. On average, they predict the company's stock price to reach $3.38 in the next year. This suggests a possible upside of 104.5% from the stock's current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. How have CERS shares performed in 2023? Cerus' stock was trading at $3.65 at the beginning of the year. Since then, CERS shares have decreased by 54.8% and is now trading at $1.65. View the best growth stocks for 2023 here. When is Cerus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our CERS earnings forecast. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) released its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.02. The biotechnology company had revenue of $39.77 million for the quarter, compared to analyst estimates of $40.90 million. Cerus had a negative net margin of 32.40% and a negative trailing twelve-month return on equity of 84.23%. What ETFs hold Cerus' stock? ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ARK Innovation ETF (ARKK). What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA). Who are Cerus' major shareholders? Cerus' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (11.10%), Sumitomo Mitsui Trust Holdings Inc. (4.38%), Senvest Management LLC (4.01%), Sepio Capital LP (1.93%), Northern Trust Corp (1.02%) and Walleye Capital LLC (1.00%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CERS) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.